Lower riskDrug recall · FDA · Published November 14, 2022
Acella Sodium Sulfacetamide Cleansing Pads: Subpotent Drug Risk
Acella Pharmaceuticals recalls 60-count cleansing pads with potential subpotent drug levels. These prescription pads may not contain enough active ingredient by end-of-shelf-life. Consumers should contact the manufacturer for details.
“Acella Sodium Sulfacetamide Cleansing Pads: Subpotent Drug Risk.” GovInfoNow, updated August 18, 2026. https://govinfonow.com/recall/34222-acella-sodium-sulfacetamide-cleansing-pads-subpotent-drug-risk. Based on FDA recall #D-0074-2023 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0074-2023%22&limit=1).
Acella Pharmaceuticals, LLC voluntarily recalled Sodium Sulfacetamide 10% Sulfur 4% Cleansing Pads on Nov. 14, 2022, after the FDA announced the product was subpotent due to failing assay specifications at the end of its shelf life.
The recall cites a subpotent drug hazard because the cleansing pads were out of specification for assay at the end-of-shelf-life 24-month period.
Context
GovInfoNow's records show Acella Pharmaceuticals, LLC has 7 other recalls on record since May 22, 2020. Other recent recalls include an April 24, 2024 recall of Sodium Sulfacetamide Cleanser due to subpotent drug issues and a Sept. 29, 2025 recall of Doxycycline Tablets for failed dissolution testing. Similar recent recalls of comparable products include a June 23, 2026 Padagis Nystatin Cream recall for subpotent drug risk and June 25, 2026 Bell Pharmaceuticals Clinere Carbamide Peroxide and CAREone 6.5% Carbamide Peroxide recalls for the same hazard.
How to tell if you have this one
Check for lot numbers 21084 or 21085 on the packaging. The product is a prescription-only cleansing pad with a net weight of 3.7g per pad, sold in 60-count cartons.
Brand
Acella Pharmaceuticals
Category
Drug
Based on the official FDA remedy
What to do — step by step
Check Product Details
Look for lot numbers 21084 or 21085 on the packaging to confirm if the product is recalled.
Where it went and when
Where it was distributed
Distributed nationwide.
Nationwide
Not listed
FDA distribution: “USA Nationwide” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 21 months after the firm started it.
1Firm started the recall
2FDA classified it Class III
3Published in FDA’s Enforcement Report
4FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
Official source: FDA Recall #D-0074-2023 (November 14, 2022) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0074-2023 to see it in context.
Plain-language summary written by qwen3:4b on August 18, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.